Penn Medicine Abramson Cancer Center, Philadelphia, PA
Leslie Andriani , Anna Jo Bodurtha Smith , Rafael Alvarez , Jonathan Heintz , Emily Meichun Ko
Background: Telemedicine rapidly increased with the COVID-19 pandemic and may be a way to reduce care disparities. Our aim was to evaluate sociodemographic (race, insurance), patient, health system, and cancer factors associated with use of telemedicine in gynecologic cancers. Methods: We conducted a retrospective cohort study of patients with documented endometrial or ovarian cancer using the nationwide de-identified electronic health record-derived Flatiron Health data. We used multi-level regression models to analyze the association of telemedicine usage during COVID-19 pandemic (2020-2021) with sociodemographic, patient, health system, and cancer factors overall. Results: Of 13,450 patients with endometrial or ovarian cancer, 14.4 % (95%CI 14.0-16.1) used telemedicine during COVID-19 for their cancer care within the Flatiron Health network. Insurance was not associated with likelihood of telemedicine in any model. Region was significantly associated with telemedicine usage across models with patients living in the Northeast more likely to use telemedicine. Conclusions: In this large cohort study, we found regional disparities across cancer types and oncology settings. Expanding access to telemedicine may improve racial and geographic disparities in gynecologic cancer.
Predictors of telemedicine usage during COVID-19 in gynecologic cancer. | ||
---|---|---|
Risk ratio | Risk ratio | |
Endometrial cancer | Ovarian Cancer | |
Patient Race | ||
Black | 0.79 (0.62-1.01) | 0.83 (0.62-1.12) |
Asian | 0.94 (0.57-1.57) | 1.44 (1.04-1.97)* |
Other | 0.83 (0.63-1.10) | 1.11 (0.93-1.34) |
Unknown race | 0.95 (0.74-1.22) | 1.06 (0.87-1.28) |
White | Reference | Reference |
Hispanic or Latino | 1.39 (1.00-1.94) | 0.77 (0.59-1.02) |
Patient Insurance | ||
Medicaid | 0.85 (0.61-1.18) | 0.82 (0.62-1.08) |
Medicare | 0.86 (0.68-1.07) | 1.02 (0.85-1.22) |
Uninsured | 0.92 (0.73-1.17) | 0.85 (0.70-1.03) |
Unknown | 0.90 (0.071-1.15) | 0.85 (0.68-1.05) |
Private insurance | Reference | Reference |
Region | ||
Southeast | 0.29 (0.22-0.38)** | 0.44 (0.36-0.53)** |
Midwest | 0.44 (0.33-0.58)** | 0.48 (0.38-0.61)** |
West | 0.56 (0.44-0.72)** | 0.67 (0.56-0.79)** |
Unknown | 1.05 (0.84-1.31) | 0.86 (0.70-1.04) |
Northeast | Reference | Reference |
Recurrent cancer | 1.11 (0.89-1.40) | 1.70 (1.49-1.93)** |
Risk ratios are adjusted for age, BMI, ECOG status, stage, and histology. *p-value<0.05. **p-value<0.001 (Bonferroni correction applied).
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Annual Meeting
First Author: Kelly E. McKinnon
2023 ASCO Annual Meeting
First Author: Min Jee Lee
2021 ASCO Annual Meeting
First Author: Christopher Manz
2022 ASCO Annual Meeting
First Author: Jenny Guadamuz